Navigation Links
ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/25/2009

lion increase in expenses related to external research-related manufacturing and regulatory and quality assurance activities related to ANX-530 and ANX-514, a $1.3 million increase in external clinical trial expenses related to ANX-514 and a $0.2 million increase in personnel costs, offset by a $5.4 million decrease in external clinical trial expenses related to CoFactor and ANX-530 and a $0.3 million decrease in non-cash, stock-based compensation expenses. R&D expenses for 2008 included non-cash, stock-based compensation expenses amounting to $0.7 million, compared to $1.0 million for 2007.

SG&A expenses increased by $1.0 million, or 12%, to $9.7 million for 2008, from $8.7 million for 2007. The increase was substantially due to a $0.7 million increase in severance expenses, a $0.4 million increase for consulting expenses related to market research, a $0.3 million increase in personnel expenses and $0.1 million increase in professional services, offset by a $0.5 million decrease in non-cash, stock-based compensation expenses. SG&A expenses for 2008 included non-cash, stock-based compensation expenses amounting to $0.9 million, compared to $1.4 million for 2007.

Revenue of $500,000 in 2008 represents a portion of a settlement payment from Theragenex, LLC. In May 2008, we settled a dispute with Theragenex arising out of its alleged breach of a license agreement and, in accordance with such settlement, Theragenex paid us $0.6 million. We recognized $0.5 million as revenue, and the remainder, $0.1 million, as other income.

Interest income and other income amounted to $0.7 million for 2008, compared to $2.2 million in 2007. The decrease in interest income and other income was primarily attributable to lower interest income based on lower invested balances, offset by $0.1 million received as part of the Theragenex settlement, which was recorded as other income.

Balance Sheet Hi
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ADVENTRX Announces Further Cost-Cutting Measures
2. ADVENTRX Provides Update on Strategic Transaction Process
3. ADVENTRX Announces Further Cost-Cutting Measures
4. ADVENTRX Exploring Strategic Options
5. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
6. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
7. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. ADVENTRX Settles Dispute With Former Licensee
10. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
11. ADVENTRX Appoints Vice President of Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... - Oncothyreon Inc. (NASDAQ: ONTY ) today ... of its Common Stock and Series A Convertible Preferred ... Series A Convertible Preferred Stock is non-voting and convertible ... will be prohibited if, as a result, the holder ... of the Common Stock then outstanding. As part of ...
(Date:9/17/2014)... 17, 2014 A biodegradable polymer ... such as bacteria, fungi, and algae into smaller ... biomass, inorganic compounds, carbon dioxide, and humus in ... base and improved costs, biodegradable polymers are proving ... alternative to conventional polymers. Primary factors that are ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... Mass. , Sept. 17, 2014 ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced that it has been ... and Trademark Office on its unique delivery system ... ) to phagocytic cells for the treatment of ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... Leadership Position in the Asia-Pacific ... ... Sept. 26 PAREXEL International,Corporation (Nasdaq: PRXL ), a ... the acquisition,of Taiwan-based APEX International Clinical Research Co., Ltd. ("APEX").,The ...
... Company Inc. (Nasdaq: NSTK ) will be hosting ... on Thursday, October 4, 2007,from 12:00 p.m. - 3:00 ... Times,Square, on 270 West 43rd Street. The luncheon event ... Chairman, President and,Chief Executive Officer and Gordon Brandt, M.D., ...
... at the Clinton Global,Initiative annual conference, PATH ... eliminate epidemic meningitis in Burkina Faso. ... Meningitis,Vaccine Project, a partnership between the World ... Institute of India Limited has been developed,for ...
Cached Biology Technology:PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd. 2PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd. 3PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd. 4PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd. 5Nastech to Host 2007 Analyst and Institutional Investor Day 2Nastech to Host 2007 Analyst and Institutional Investor Day 3PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 2PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 3
(Date:9/17/2014)... Social Evolution and Yale University offers compelling support for ... can partially predict the likelihood of being diagnosed with ... in life. The study analyzed medical records of 1.75 ... to 30 years, and adjusted for almost all other ... the Proceedings of the Royal Society, London B ...
(Date:9/17/2014)... Mutations in the human retinoblastoma protein gene are ... University scientists have turned to fruit fly eyes to ... , In a paper featured on the cover of ... Chemistry , Michigan State University researchers provide the first ... those present in the human cancer gene, said Irina ...
(Date:9/17/2014)... 1960s. The typical development phases of trees and stands ... as much as 70 percent. This was the outcome ... Universitt Mnchen based on long-term data from experimental forest ... findings were published recently in Nature Communications . ... topic, with the very survival of large forest ecosystems ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Abnormal properties of cancer protein revealed in fly eyes 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... Ohio Salmonella cells have hijacked the protein-building ... suggests. Scientists say that these bacteria have modified what ... beta form of an amino acid as opposed to ... Beta versions of amino acids occur in nature ...
... NEW YORK, July 6, 2011 Reportlinker.com announces ... in its catalogue: Biobanking: Technologies ... REPORT HIGHLIGHTS ... * An overview of biobanks by types: Population, ...
... ,   SPO (SPOM.OB), a leading ... that it has entered into an Investment Agreement,with Dutchess Opportunity ... Under the terms of the signed agreement, for a ... and Dutchess the,obligation to purchase common stock at a 6% ...
Cached Biology News:Salmonella stays deadly with a 'beta' version of cell behavior 2Salmonella stays deadly with a 'beta' version of cell behavior 3Biobanking: Technologies and Global Markets 2Biobanking: Technologies and Global Markets 3Biobanking: Technologies and Global Markets 4Biobanking: Technologies and Global Markets 5Biobanking: Technologies and Global Markets 6Biobanking: Technologies and Global Markets 7Biobanking: Technologies and Global Markets 8Biobanking: Technologies and Global Markets 9Biobanking: Technologies and Global Markets 10Biobanking: Technologies and Global Markets 11Biobanking: Technologies and Global Markets 12Biobanking: Technologies and Global Markets 13SPO Secures Equity Line Facility of US$5 Million 2SPO Secures Equity Line Facility of US$5 Million 3SPO Secures Equity Line Facility of US$5 Million 4
Goat polyclonal to T7 tag (Agarose) Immunogen: Goats were immunized with MASMTGGQQMG (T7) conjugated to KLH.After multiple immunizations in Freund's adjuvant, serum was collected....
... The features we add to WinList ... the product every day. Features like automatic ... are the result of good suggestions, thoughtful ... of the features you depend on are ...
C/EBPdelta Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
Biology Products: